Clinical Trials Browser

Phase 3 × Carcinoma, Renal Cell × Axitinib × Clear all

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01599754 2019-09-20

ATLAS

Phase 3 Terminated

724 enrolled 17 charts

Carcinoma, Renal Cell